Printer Friendly

STERLING WINTHROP'S U.S. PHARMACEUTICALS UNIT, SANOFI WINTHROP PHARMACEUTICALS, AND MEDRAD, ANNOUNCE DEVELOPMENT AGREEMENT

 STERLING WINTHROP'S U.S. PHARMACEUTICALS UNIT, SANOFI WINTHROP
 PHARMACEUTICALS, AND MEDRAD, ANNOUNCE DEVELOPMENT AGREEMENT
 NEW YORK, Oct. 26 /PRNewswire/ -- Sterling Winthrop Inc. today announced that Sanofi Winthrop Pharmaceuticals (U.S.A.) and Medrad, Inc. have signed an agreement that provides Sanofi Winthrop access to license Medrad technology for use in the development of prefilled syringes that are compatible with Medrad's current generation of power injection systems.
 According to Daniel Peters, executive vice president of Sanofi Winthrop Pharmaceuticals (U.S.A.), "This agreement provides mutual benefit for two industry leaders, Sanofi Winthrop, a pioneer in the development of nonionic contrast media and Medrad, the market leader in power injection of contrast media."
 Thomas H. Witmer, president and chief executive officer of Medrad, commented, "Medrad is pleased to be able to enter into a development agreement with the leading manufacturer of nonionic contrast media for angiography and computed tomography to bring added value to our mutual customers."
 Sanofi Winthrop Pharmaceuticals is the U.S. marketing unit of Sterling Winthrop Inc., a worldwide developer, manufacturer and marketer of pharmaceuticals and consumer health products. Key products marketed by Sanofi Winthrop in the U.S. are: Omnipaque (iohexol), a leading nonionic contrast agent in the U.S. and Canada; Inocor I.V. (intravenous amrinone) and Primacor I.V. (intravenous milrinone) for congestive heart failure; Talwin Nx (pentazocine and naloxone hydrochloride) analgesic; Carpuject line of injectables in pre-filled syringes; Plaquenil (hydroxychloroquine) for rheumatoid arthritis and lupus erythematosus; and Danocrine (danazol) for endometriosis.
 Medrad, Inc. is a leading developer, manufacturer, and marketer of equipment and disposable products which enhance the clarity of medical images of the human body. Medrad's products are sold to hospitals and medical imaging centers in more than 55 countries and are used in angiography, computed tomography, and magnetic resonance imaging procedures.
 -0- 10/26/92
 /CONTACT: Diane C. Iselin, 212-907-2341, or Terry G. Kelley, 212-907-3009, both of Sterling Winthrop, Inc./ CO: Sterling Winthrop Inc.; Medrad, Inc. ST: New York IN: MTC SU:


LR-OS -- NY045 -- 4876 10/26/92 14:03 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 26, 1992
Words:338
Previous Article:PICTURETEL LEARNING SOLUTION SET HELPS REDEFINE THE WAY THE WORLD LEARNS
Next Article:PRATT & WHITNEY AND RUSSIAN FIRM JOIN FORCES TO MARKET ROCKET ENGINES IN U.S.
Topics:


Related Articles
STERLING WINTHROP AND BIOMIRA SIGN AGREEMENTS FOR THE DEVELOPMENT OF ANTIBODY-BASED CANCER PRODUCTS
BIOMIRA AND STERLING WINTHROP SIGN AGREEMENTS FOR THE DEVELOPMENT OF ANTIBODY-BASED CANCER PRODUCTS
STERLING WINTHROP ANNOUNCES SANOFI WINTHROP LICENSING AGREEMENT FOR PREFILLED NEEDLE-FREE SYRINGE WITH BAXTER HEALTHCARE
STERLING WINTHROP ANNOUNCES SANOFI WINTHROP LICENSING AGREEMENT FOR PREFILLED NEEDLE-FREE SYRINGE WITH BAXTER
INNOVATIVE TOOL ENRICHES EDUCATION: STERLING WINTHROP DONATION BRINGS MOBILE CLASSROOM 2000 TO WASHINGTON, D.C. PUBLIC SCHOOL SYSTEM
NEORX TO GRANT LICENSE FOR RHENIUM CANCER THERAPY TO STERLING WINTHROP AS PART OF A $10 MILLION AGREEMENT
MEDCO RESEARCH'S ADENOCARD DRUG IS APPROVED FOR MARKETING IN SEVEN EUROPEAN COUNTRIES
STERLING WINTHROP INC. AND ADVANCED MAGNETICS, INC. ANNOUNCE MRI CONTRAST AGENT LICENSE AND MARKETING AGREEMENT
CLOSING COMPLETED, SANOFI NAMES MANAGEMENT TEAM FOR PHARMACEUTICAL DIVISION
JOSEPH TARTAGLIA JOINS MEDTRONIC INTERVENTIONAL VASCULAR AS VICE PRESIDENT, PRODUCT DEVELOPMENT/OPERATIONS IN SAN DIEGO

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters